Clinical trial
Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With…
NCT00268229 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00268229 |
|---|---|
| Title | Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia |
| Official title | A Phase I Trial of Imatinib Mesylate (Gleevec, Formerly Known as STI571) in Combination With Daunorubicin and Cytarabine for C-kit Positive Relapsed AML |
| Lead sponsor | The Cleveland Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | cytarabine, daunorubicin hydrochloride, imatinib mesylate |
| Enrollment | 21 |
| Start date | Jul 1, 2003 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Dec 22, 2005 |
| Last update posted | Feb 15, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: